TG Therapeutics (NASDAQ:TGTX – Get Free Report) released its quarterly earnings data on Monday. TG Therapeutics Stock PerformanceTG Therapeutics stock opened at $49.89 on Monday. TG Therapeutics has a 1 year low of $25.28 and a 1 year high of $59.30. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology. In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.Further ReadingReceive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.